Skip to content

Evofem Biosciences, Inc.

EVFM · OTCM

CIK 1618835fmd_0E4CSPX34A15QBWXNVPJZ2HHD1Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2013 to Jun 30, 2026, 51 periods

Latest annual · FY2025

Millions
Total revenues
20
Gross profit
16
Operating income
3
Net income
0
Free cash flow
(2)

Latest quarter · Q2 FY2026

Millions
Total revenues
3
Gross profit
2
Operating income
(2)
Net income
(11)
Free cash flow
(3)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+6.2%
Revenue, 5 yearsFY2020 to FY2025
+114.4%
Net income, 5 yearsFY2020 to FY2025
n/m

Evofem Biosciences, Inc. (EVFM) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$20.2 million$19.4 million+4.2%10-K 2026-03-11 · proof
Gross profit$15.6 million$15.5 million+0.2%10-K 2026-03-11 · proof
Operating income$3.4 million-$7.7 million10-K 2026-03-11 · proof
Net income$391,000-$8.9 million10-K 2026-03-11 · proof
Cash from operating activities-$2 million-$3.9 million10-K 2026-03-11 · proof
Free cash flow-$2 million-$3.9 million10-K 2026-03-11 · proof
Total assets$20.3 million$23.8 million-14.8%10-K 2026-03-11 · proof
Total liabilities$89.7 million$90.3 million-0.6%10-K 2026-03-11 · proof
Cash and cash equivalents$578,000$741,000-22%10-K 2026-03-11 · proof
What was Evofem Biosciences, Inc. (EVFM)'s revenue in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported revenue of $20.2 million for fiscal 2025 (the year ended Dec 31, 2025), against $19.4 million the year before (+4.2%). Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What was Evofem Biosciences, Inc. (EVFM)'s gross profit in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported gross profit of $15.6 million for fiscal 2025 (the year ended Dec 31, 2025), against $15.5 million the year before (+0.2%). Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What was Evofem Biosciences, Inc. (EVFM)'s operating income in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported operating income of $3.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$7.7 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What was Evofem Biosciences, Inc. (EVFM)'s net income in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported net income of $391,000 for fiscal 2025 (the year ended Dec 31, 2025), against -$8.9 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What was Evofem Biosciences, Inc. (EVFM)'s cash from operating activities in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported cash from operating activities of -$2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.9 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What was Evofem Biosciences, Inc. (EVFM)'s free cash flow in fiscal 2025?
Evofem Biosciences, Inc. (EVFM) reported free cash flow of -$2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$3.9 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What are Evofem Biosciences, Inc. (EVFM)'s total assets?
As of Dec 31, 2025, Evofem Biosciences, Inc. (EVFM) reported total assets of $20.3 million, against $23.8 million a year earlier (-14.8%). Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What are Evofem Biosciences, Inc. (EVFM)'s total liabilities?
As of Dec 31, 2025, Evofem Biosciences, Inc. (EVFM) reported total liabilities of $89.7 million, against $90.3 million a year earlier (-0.6%). Source: the 10-K filed with the SEC on Mar 11, 2026. SEC
What are Evofem Biosciences, Inc. (EVFM)'s cash and cash equivalents?
As of Dec 31, 2025, Evofem Biosciences, Inc. (EVFM) reported cash and cash equivalents of $578,000, against $741,000 a year earlier (-22%). Source: the 10-K filed with the SEC on Mar 11, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:EVFM&period_type=annual&limit=5"

Information only, not investment advice.